Wall Street brokerages expect Xeris Pharmaceuticals, Inc. (NASDAQ:XERS – Get Rating) to report sales of $22.97 million for the current quarter, according to Zacks. Four analysts have made estimates for Xeris Pharmaceuticals’ earnings. The highest sales estimate is $24.10 million and the lowest is $22.28 million. Xeris Pharmaceuticals posted sales of $8.05 million during the […]
Wall Street brokerages expect Xeris Pharmaceuticals, Inc. (NASDAQ:XERS – Get Rating) to post earnings of ($0.24) per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Xeris Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.22). Xeris Pharmaceuticals […]
Squarepoint Ops LLC lowered its holdings in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS – Get Rating) by 61.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,595 shares of the company’s stock after selling 20,008 shares during the period. Squarepoint […]
Veery Capital LLC purchased a new position in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS – Get Rating) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,544 shares of the company’s stock, valued at approximately $37,000. Other hedge funds and other institutional […]